Primary microparticles and agglomerates of morphine for nasal insufflation

Journal of Pharmaceutical Sciences

Volumn 95, Issue 12, 2006, Pages 2553-2561

  Russo, Paola ^a,b   Sacchetti, Cecilia ^a   Pasquali, Irene ^a   Bettini, Ruggero ^a   Massimo, Gina ^a   Colombo, Paolo ^a   Rossi, Alessandra ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Agglomerates; In vitro models; Microparticles; Morphine; Nasal drug delivery; Powder technology

Indexed keywords

BETA CYCLODEXTRIN; EXCIPIENT; LACTOSE; MANNITOL; MORPHINE; PHOSPHATIDYLCHOLINE; TREHALOSE;

AERATION; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; IN VITRO STUDY; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; RABBIT; SPRAY DRYING; X RAY DIFFRACTION;

EID: 33846248811     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20604     Document Type: Article

References (16)

1. Sacchetti C, Artusi M, Santi P, Colombo P. 2002. Caffeine microparticles for nasal administration obtained by spray drying. Int J Pharm 242:335-339.
2. Russo P, Buttini F, Sonvico F, Bettini R, Massimo G, Sacchetti C, Colombo P, Santi P. 2004. Chimeral agglomerates of microparticles for the administration of caffeine nasal powders. J Drug Del Sci Tech 14:423-434.
3. Ilium L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS. 2002. Intranasal delivery of morphine. J Pharmacol Exp Ther 301:391-400.
4. Bourget P, Lesne-Hulin A, Quinquis-Desmaris V. 1995. Study of the bioequivalence of two controlled-release formulations of morphine. Int J Clin Pharmacol Ther 33:588-594.
5. Westin U, Piras E, Jansson B, Bergstrom U, Dahlin M, Brittebo E, Bjork E. 2005. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 24:565-573.
6. Gillis JC, Benfield P, Goa KL. 1995. Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 50:157-175.
7. Fitzgibbon D, Morgan D, Dockter D, Barry C, Kharasch ED. 2003. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 106:309-315.
8. Pavis H, Wilcock A, Edgecombe J, Carr D, Manderson C, Church A, Fisher A. 2002. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manage 24:598-602.
9. Betbeder D, Sperandio S, Latapie JP, de Nadai J, Etienne A, Zajac JM, Frances B. 2000. Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 17:743-748.
10. Achari RG, Behl CR, deMeireles JC, Dua R, Romeo VD, Sileno AP. 2000. Methods comprising intranasal morphine. U.S. Patent No 6, 677, 346.
11. Illum L. 1997. Composition for nasal administration. U.S. Patent No 5, 629, 011.
12. Illum L, Watts P, Lafferty I, Smith A. 2002. Salts of oppioid analgesics, particularly morphine, and methods of using same. U.S. Patent No 6, 387, 917.
13. Hussain AA. 1984. Method of administering narcotic antagonists and analgesics and novel dosage forms containing same. U.S. Patent No 4, 464, 378.
14. Behl CR, Romeo VD, Sileno AP. 2002. Compositions and methods comprising morphine gluconate. U.S. Patent No 6, 451, 848.
15. Vermeire A, Remon JP. 1999. Stability and compatibility of morphine. Int J Pharm 187:17-51.
16. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, Smith A, Ilium L. 2002. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 19:998-1008.